The HARMONY-EHA webinar (June 4, 2020) provided a unique opportunity for HARMONY leaders to collaborate and discuss the role of the HARMONY COVID-19 Data Platform in increasing our knowledge of COVID-19 and its impact on patients with Hematologic Malignancies. The webinar is now available for viewing on demand.
Overview of topics discussed
HARMONY in COVID-19 pandemic: the power of Big Data to address emerging needs
Jesus Maria Hernandez Rivas, Professor of Hematology, University of Salamanca, IBSAL, Hospital Universitario de Salamanca, Spain – HARMONY Coordinator
Professor Hernandez Rivas discussed the collaboration between HARMONY and the European Health Data & Evidence Network (EHDEN), which aims to incorporate data on patients with COVID-19 into the HARMONY COVID-19 Data Platform. He also mentioned how organizations can work together to share data with HARMONY to enhance our understanding of COVID-19 and Hematological Malignancies.
HARMONY’s case report form for COVID-19 in patients with Hematologic Malignancies
Guillermo Sanz, Head of Hematology, Hospital Universitario La Fe, Valencia, Spain – HARMONY Co-Chair
Professor Sanz explained how the HARMONY case report form (CRF) has been adapted to provide a user-friendly way to harmonize data from patients with COVID-19 on the HARMONY COVID-19 Data Platform. He provided a walkthrough of how the new CRF form can be completed.
European study on myeloproliferative neoplasms and COVID-19: a HARMONY research project
Tiziano Barbui, Scientific Director of the Research Foundation Ospedale Papa Giovanni XXIII, Bergamo, Italy
Professor Barbui provided an overview of HARMONY’s new research project on myeloproliferative neoplasms (MPN) and COVID-19. He discussed the similarities between MPN- and COVID-19-related inflammatory thrombosis and how harmonizing data on both diseases could inform treatment strategies for patients with concomitant disease. Professor Barbui also shared early findings from the study.
Live Q&A
Moderated by Francesco Cerisoli, Head of Research and Mentoring at the EHA
The live Q&A sessions allowed members of the audience to engage with the speakers and ask any relevant questions about HARMONY and COVID-19. Key questions asked included:
Find out the answers to these important questions by watching the webinar; follow the link at the top of the page or click here.
The HARMONY Alliance is a public-private partnership for Big Data in Hematology, established in January 2017. Our mission is to unlock and spread valuable knowledge on Hematologic Malignancies (blood cancers) among a large number of stakeholders. The ultimate goal of HARMONY is to harness and mine Big Data to speed up the development of improved treatments and treatment strategies for patients.
We currently have 53 Partners and 41 Associated Members from across 17 European countries, including 9 pharmaceutical companies and 7 European Patient Umbrella Organizations. The HARMONY Alliance is funded by the Innovative Medicines Initiative (IMI).
• Read more | Become involved
HARMONY takes action to manage COVID-19
• Read about the HARMONY COVID19 Data Platform | View more COVID19 activities
Receive the latest news. Click here to subscribe!
Public-private partnership for Big Data in Hematology
HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
HARMONY Coordination Office
Institute of Biomedical Research of
Salamanca (IBSAL)
Salamanca, Spain
HARMONY Communications
European Hematology Association (EHA)
The Hague, The Netherlands
